PRQR Stock Analysis: ProQR Therapeutics N.V.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndro
- Latest close
- $1.64
- 20-day change
- -21.77%
- Trend state
- LEAN BEAR
- Classification
- Healthcare · Biotechnology
Market context
ProQR Therapeutics N.V. moved -21.77% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BEAR.
Latest report
The latest cached company filing period (FY2025 · $15.9M revenue · -$42.2M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 4.0/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.